Skip to main content
. Author manuscript; available in PMC: 2023 Dec 18.
Published in final edited form as: Biomaterials. 2021 Oct 2;278:121140. doi: 10.1016/j.biomaterials.2021.121140

Table 3.

Comparison of pharmacokinetic parameters of POXOL hl-PM and Abraxane® in rhesus macaque

Parametersa POXOL hl-PM Abraxane® POxb

Total Protein-bound Encapsulated Free Total Protein-bound Encapsulated Free Total

Tmax(h) 0.6 0.6 0.6 0.6 0.5 0.5 0.5 0.5 0.58
Cmax(ng/mL) 14944.0 9586.5 4301.5 1649.0 17899.5 11956.7 4127.0 1815.8 296602.6
AUCall(ng•h/mL) 22198.2 15072.5 4835.9 2567.6 22276.2 15801.8 3991.1 2460.5 2797225.9
AUCinf(ng•h/mL) 22319.6 15123.9 4918.7 2574.7 22440.2 15874.3 4032.3 2474.5 2837613.5
CL (mL/h•kg) 542.4 798.7 2440.7 4793.4 546.1 776.6 2999.6 4935.0 10.57
t1/2(h) 7.6 6.8 10.7 6.6 9.3 6.8 8.1 8.8 7.51
MRT (h) 4.0 4.0 3.8 3.5 4.1 4.1 4.0 4.0 9.8
VSS(mL/kg) 2310.9 3286.6 11890.8 17440.1 2552.4 3486.1 13896.4 21670.9 110.99
a

Tmax, time of maximum concentration; Cmax, maximum plasma concentration; AUCall, area under the curve from all time points; AUCinf, area under the curve until infinite time; CL, clearance; t1/2, half life; MRT, mean residence time; VSS, apparent volume of distribution at steady state

b

PK parameter of POx was determined from the PET/CT study described in section Result (section 3.4). Each datum represents mean of 2 animals; individual animal datum can be found in Table S5.